Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Multiple sclerosis: association with HL-A3.
Extavia Prescribing Information
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Copaxone
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease.
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1 a) products administered intramuscularly in healthy male and female volunteers.
Receptos to deliver scientific presentation at Digestive Disease Week 2012 about the therapeutic role of RPC1063 in inflammatory bowel disease
Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
[Assessment of the pain patients with the multiple sclerosis after applying the physiotherapy treatment].
PML in a patient treated with fumaric acid.

Pages